Skip to main content
NCBI home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1993 Feb;77(2):110–114. doi: 10.1136/bjo.77.2.110

The EP2 receptor is the predominant prostanoid receptor in the human ciliary muscle.

T Matsuo 1, M S Cynader 1
PMCID: PMC504442  PMID: 8435410

Abstract

Prostaglandins can reduce intraocular pressure by increasing uveoscleral outflow. We have previously demonstrated that the human ciliary muscle was a zone of concentration for binding sites (receptors) for prostaglandin F2 alpha and for prostaglandin E2. Here, we try to elucidate the types of prostanoid receptors in the ciliary muscle using competitive ligand binding studies in human eye sections and computer assisted autoradiographic densitometry. Saturation binding curves showed that the human ciliary muscle had a large number of binding sites with a high affinity for prostaglandin E2 compared with prostaglandin D2 and F2 alpha. The binding of tritiated prostaglandin E2 and F2 alpha in the ciliary muscle was displaced most effectively by prostaglandin E2 and 11-deoxy prostaglandin E1 (a selective EP2 prostanoid receptor agonist), whereas the binding of prostaglandin D2 was displaced most effectively by prostaglandin E2 and D2. These results indicate that the dominant prostanoid receptor in the human ciliary muscle is the EP2 subclass and that there is also a small number of DP receptors.

Full text

PDF
110

Images in this article

111Image
on p.111

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aula P., Kaila T., Huupponen R., Salminen L., Iisalo E. Prostaglandin F2 alpha binding to bovine ocular and synthetic melanins in vitro. Pharmacol Toxicol. 1989 Aug;65(2):100–103. doi: 10.1111/j.1600-0773.1989.tb01136.x. [DOI] [PubMed] [Google Scholar]
  2. Bhattacherjee P., Csukas S., Paterson C. A. Prostaglandin E2 binding sites in bovine iris-ciliary body. Invest Ophthalmol Vis Sci. 1990 Jun;31(6):1109–1113. [PubMed] [Google Scholar]
  3. Bito L. Z. Comparison of the ocular hypotensive efficacy of eicosanoids and related compounds. Exp Eye Res. 1984 Feb;38(2):181–194. doi: 10.1016/0014-4835(84)90102-7. [DOI] [PubMed] [Google Scholar]
  4. Bito L. Z., Draga A., Blanco J., Camras C. B. Long-term maintenance of reduced intraocular pressure by daily or twice daily topical application of prostaglandins to cat or rhesus monkey eyes. Invest Ophthalmol Vis Sci. 1983 Mar;24(3):312–319. [PubMed] [Google Scholar]
  5. Bito L. Z., Srinivasan B. D., Baroody R. A., Schubert H. Noninvasive observations on eyes of cats after long-term maintenance of reduced intraocular pressure by topical application of prostaglandin E2. Invest Ophthalmol Vis Sci. 1983 Mar;24(3):376–380. [PubMed] [Google Scholar]
  6. Camras C. B., Siebold E. C., Lustgarten J. S., Serle J. B., Frisch S. C., Podos S. M., Bito L. Z. Maintained reduction of intraocular pressure by prostaglandin F2 alpha-1-isopropyl ester applied in multiple doses in ocular hypertensive and glaucoma patients. Ophthalmology. 1989 Sep;96(9):1329–1337. doi: 10.1016/s0161-6420(89)32717-5. [DOI] [PubMed] [Google Scholar]
  7. Crawford K., Kaufman P. L. Pilocarpine antagonizes prostaglandin F2 alpha-induced ocular hypotension in monkeys. Evidence for enhancement of Uveoscleral outflow by prostaglandin F2 alpha. Arch Ophthalmol. 1987 Aug;105(8):1112–1116. doi: 10.1001/archopht.1987.01060080114039. [DOI] [PubMed] [Google Scholar]
  8. Dong Y. J., Jones R. L., Wilson N. H. Prostaglandin E receptor subtypes in smooth muscle: agonist activities of stable prostacyclin analogues. Br J Pharmacol. 1986 Jan;87(1):97–107. doi: 10.1111/j.1476-5381.1986.tb10161.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Eglen R. M., Whiting R. L. Characterization of the prostanoid receptor profile of enprostil and isomers in smooth muscle and platelets in vitro. Br J Pharmacol. 1989 Dec;98(4):1335–1343. doi: 10.1111/j.1476-5381.1989.tb12682.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Eriksson L. O., Larsson B., Andersson K. E. Biochemical characterization and autoradiographic localization of [3H]PGE2 binding sites in rat kidney. Acta Physiol Scand. 1990 Jul;139(3):405–415. doi: 10.1111/j.1748-1716.1990.tb08941.x. [DOI] [PubMed] [Google Scholar]
  11. Gabelt B. T., Kaufman P. L. Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey. Exp Eye Res. 1989 Sep;49(3):389–402. doi: 10.1016/0014-4835(89)90049-3. [DOI] [PubMed] [Google Scholar]
  12. Giuffrè G. The effects of prostaglandin F2 alpha in the human eye. Graefes Arch Clin Exp Ophthalmol. 1985;222(3):139–141. doi: 10.1007/BF02173538. [DOI] [PubMed] [Google Scholar]
  13. Goh Y., Nakajima M., Azuma I., Hayaishi O. Prostaglandin D2 reduces intraocular pressure. Br J Ophthalmol. 1988 Jun;72(6):461–464. doi: 10.1136/bjo.72.6.461. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Hirata M., Hayashi Y., Ushikubi F., Yokota Y., Kageyama R., Nakanishi S., Narumiya S. Cloning and expression of cDNA for a human thromboxane A2 receptor. Nature. 1991 Feb 14;349(6310):617–620. doi: 10.1038/349617a0. [DOI] [PubMed] [Google Scholar]
  15. Kennedy I., Coleman R. A., Humphrey P. P., Levy G. P., Lumley P. Studies on the characterisation of prostanoid receptors: a proposed classification. Prostaglandins. 1982 Nov;24(5):667–689. doi: 10.1016/0090-6980(82)90036-3. [DOI] [PubMed] [Google Scholar]
  16. Lee P. Y., Shao H., Xu L. A., Qu C. K. The effect of prostaglandin F2 alpha on intraocular pressure in normotensive human subjects. Invest Ophthalmol Vis Sci. 1988 Oct;29(10):1474–1477. [PubMed] [Google Scholar]
  17. Matsuo T., Cynader M. S. Localisation of prostaglandin F2 alpha and E2 binding sites in the human eye. Br J Ophthalmol. 1992 Apr;76(4):210–213. doi: 10.1136/bjo.76.4.210. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Nilsson S. F., Samuelsson M., Bill A., Stjernschantz J. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-1-isopropylester in the cynomolgus monkey. Exp Eye Res. 1989 May;48(5):707–716. doi: 10.1016/0014-4835(89)90011-0. [DOI] [PubMed] [Google Scholar]
  19. Protzman C. E., Woodward D. F. Prostanoid-induced blood-aqueous barrier breakdown in rabbits involves the EP2 receptor subtype. Invest Ophthalmol Vis Sci. 1990 Nov;31(11):2463–2466. [PubMed] [Google Scholar]
  20. Shimizu T., Yamashita A., Hayaishi O. Specific binding of prostaglandin D2 to rat brain synaptic membrane. Occurrence, properties, and distribution. J Biol Chem. 1982 Nov 25;257(22):13570–13575. [PubMed] [Google Scholar]
  21. Stern F. A., Bito L. Z. Comparison of the hypotensive and other ocular effects of prostaglandins E2 and F2 alpha on cat and rhesus monkey eyes. Invest Ophthalmol Vis Sci. 1982 May;22(5):588–598. [PubMed] [Google Scholar]
  22. Villumsen J., Alm A. Prostaglandin F2 alpha-isopropylester eye drops: effects in normal human eyes. Br J Ophthalmol. 1989 Jun;73(6):419–426. doi: 10.1136/bjo.73.6.419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Villumsen J., Alm A., Söderström M. Prostaglandin F2 alpha-isopropylester eye drops: effect on intraocular pressure in open-angle glaucoma. Br J Ophthalmol. 1989 Dec;73(12):975–979. doi: 10.1136/bjo.73.12.975. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Waterbury L. D., Eglen R. M., Faurot G. F., Cooper G. F. EP3, but not EP2, FP, or TP prostanoid-receptor stimulation may reduce intraocular pressure. Invest Ophthalmol Vis Sci. 1990 Dec;31(12):2560–2567. [PubMed] [Google Scholar]
  25. Woodward D. F., Burke J. A., Williams L. S., Palmer B. P., Wheeler L. A., Woldemussie E., Ruiz G., Chen J. Prostaglandin F2 alpha effects on intraocular pressure negatively correlate with FP-receptor stimulation. Invest Ophthalmol Vis Sci. 1989 Aug;30(8):1838–1842. [PubMed] [Google Scholar]
  26. Woodward D. F., Hawley S. B., Williams L. S., Ralston T. R., Protzman C. E., Spada C. S., Nieves A. L. Studies on the ocular pharmacology of prostaglandin D2. Invest Ophthalmol Vis Sci. 1990 Jan;31(1):138–146. [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES